Search Results - "DUTCHER, Janice"

Gender effects in cancer treatment and outcome by Dutcher, Janice P.

Get full text

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial by Haas, Naomi B, Dr, Manola, Judith, MS, Uzzo, Robert G, Prof, Flaherty, Keith T, MD, Wood, Christopher G, Prof, Kane, Christopher, Prof, Jewett, Michael, Prof, Dutcher, Janice P, Prof, Atkins, Michael B, Prof, Pins, Michael, Prof, Wilding, George, Prof, Cella, David, Prof, Wagner, Lynne, Prof, Matin, Surena, Prof, Kuzel, Timothy M, Prof, Sexton, Wade J, Prof, Wong, Yu-Ning, MD, Choueiri, Toni K, MD, Pili, Roberto, Prof, Puzanov, Igor, MD, Kohli, Manish, MD, Stadler, Walter, Prof, Carducci, Michael, Prof, Coomes, Robert, DiPaola, Robert S, Prof

“…Summary Background Renal-cell carcinoma is highly vascular, and proliferates primarily through dysregulation of the vascular endothelial growth factor (VEGF)…”
Get full text

Management of hepatitis B in the era of checkpoint inhibition by Dutcher, Janice

“…Hepatitis B virus (HBV) is a major global health concern, affecting more than 350 million people worldwide. Its management in the setting of cancer treatment…”
Get full text

Update on the biology and management of renal cell carcinoma by Dutcher, Janice P

“…Renal cell cancer (RCC) (epithelial carcinoma of the kidney) represents 2%–4% of newly diagnosed adult tumors. Over the past 2 decades, RCC has been better…”
Get full text

“Pseudoprogression”: more than semantics by Dutcher, Janice P.

Get full text

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma by RINI, Brian I, WILDING, George, HUDES, Gary, STADLER, Walter M, KIM, Sinil, TARAZI, Jamal, ROSBROOK, Brad, TRASK, Peter C, WOOD, Laura, DUTCHER, Janice P

“…To investigate the efficacy and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3…”
Get full text

Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees by Wiernik, Peter H, Dutcher, Janice P

“…Although reports of familial clustering of hematologic malignancies have appeared for decades, the cause(s) of this uncommon occurrence is still not completely…”
Get full text

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation by Correa, Andres F, Jegede, Opeyemi, Haas, Naomi B, Flaherty, Keith T, Pins, Michael R, Messing, Edward M, Manola, Judith, Wood, Christopher G, Kane, Christopher J, Jewett, Michael A S, Dutcher, Janice P, DiPaola, Robert S, Carducci, Michael A, Uzzo, Robert G

“…To validate currently used recurrence prediction models for renal cell carcinoma (RCC) by using prospective data from the ASSURE (ECOG-ACRIN E2805; Adjuvant…”
Get full text

Recent developments in the treatment of renal cell carcinoma by Dutcher, Janice P.

“…Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and…”
Get full text

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 by RINI, Brian I, HALABI, Susan, SMALL, Eric J, ROSENBERG, Jonathan E, STADLER, Walter M, VAENA, Daniel A, ARCHER, Laura, ATKINS, James N, PICUS, Joel, CZAYKOWSKI, Piotr, DUTCHER, Janice

“…Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha)…”
Get full text

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 by RINI, Brian I, HALABI, Susan, DUTCHER, Janice, SMALL, Eric J, ROSENBERG, Jonathan E, STADLER, Walter M, VAENA, Daniel A, OU, San-San, ARCHER, Laura, ATKINS, James N, PICUS, Joel, CZAYKOWSKI, Piotr

“…Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa…”
Get full text

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis by Rini, Brian I., Garrett, May, Poland, Bill, Dutcher, Janice P., Rixe, Olivier, Wilding, George, Stadler, Walter M., Pithavala, Yazdi K., Kim, Sinil, Tarazi, Jamal, Motzer, Robert J.

“…Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second‐line therapy for advanced renal…”
Get full text

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma by Correa, Andres F., Jegede, Opeyemi A., Haas, Naomi B., Flaherty, Keith T., Pins, Michael R., Adeniran, Adebowale, Messing, Edward M., Manola, Judith, Wood, Christopher G., Kane, Christopher J., Jewett, Michael A.S., Dutcher, Janice P., DiPaola, Robert S., Carducci, Michael A., Uzzo, Robert G.

“…Risk stratification for localized renal cell carcinoma (RCC) relies heavily on retrospective models, limiting their generalizability to contemporary cohorts…”
Get full text

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804) by Flaherty, Keith T, Manola, Judith B, Pins, Michael, McDermott, David F, Atkins, Michael B, Dutcher, Janice J, George, Daniel J, Margolin, Kim A, DiPaola, Robert S

“…On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and other…”
Get full text

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial by Haas, Naomi B, Manola, Judith, Dutcher, Janice P, Flaherty, Keith T, Uzzo, Robert G, Atkins, Michael B, DiPaola, Robert S, Choueiri, Toni K

“…Given recently published results of a 750-patient adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy for treating…”
Get more information

Interleukin‐2 Can Cure Kidney Cancer by Dutcher, Janice P., Wiernik, Peter H.

“…As new immunotherapy treatment options become available, one must focus on the goals of extending survival and of potential cure…”
Get full text

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition by Buchbinder, Elizabeth I, Dutcher, Janice P, Daniels, Gregory A, Curti, Brendan D, Patel, Sapna P, Holtan, Shernan G, Miletello, Gerald P, Fishman, Mayer N, Gonzalez, Rene, Clark, Joseph I, Richart, John M, Lao, Christopher D, Tykodi, Scott S, Silk, Ann W, McDermott, David F

“…Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies…”
Get full text

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma by McDermott, David F, Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A, Clark, Joseph I, Sosman, Jeffrey A, Dutcher, Janice P, Logan, Theodore F, Curti, Brendan D, Ernstoff, Marc S, Appleman, Leonard, Wong, Michael K K, Khushalani, Nikhil I, Oleksowicz, Leslie, Vaishampayan, Ulka N, Mier, James W, Panka, David J, Bhatt, Rupal S, Bailey, Alexandra S, Leibovich, Bradley C, Kwon, Eugene D, Kabbinavar, Fairooz F, Belldegrun, Arie S, Figlin, Robert A, Pantuck, Allan J, Regan, Meredith M, Atkins, Michael B

“…High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response…”
Get full text

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus by Maroto, Jose Pablo, Hudes, Gary, Dutcher, Janice P, Logan, Theodore F, White, Charles S, Krygowski, Mizue, Cincotta, Maria, Shapiro, Mark, Duran, Ignacio, Berkenblit, Anna

“…Pneumonitis has occurred in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). In a phase III study of patients with previously…”
Get full text

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial by Lee, Ziho, Jegede, Opeyemi A, Haas, Naomi B, Pins, Michael R, Messing, Edward M, Manola, Judith, Wood, Christopher G, Kane, Christopher J, Jewett, Michael A S, Flaherty, Keith T, Dutcher, Janice P, DiPaola, Robert S, Uzzo, Robert G

“…We describe what is to our knowledge a novel classification system for local recurrence after surgery of renal cell carcinoma. We assessed its prognostic…”
Get full text